RANK 3
Revenue 928.41
crore |
Panacea Biotec |
JMD |
Dr
Rajesh Jain |
Business |
Pharmaceuticals,
biopharmaceuticals
and
vaccines |
Start-up
Year: 1978 |
Address:
B-1, Extn./G-3, Mohan Cooperative Industrial Estate, Mathura Road, New
Delhi-110 044 |
Tel:
+91-11-41679000, 41678000 |
Fax:
+91-11-41679070, 26940199 |
Website:
www.panaceabiotec.com |
Leveraging on effective business
strategy and successful execution, Panacea's biotech revenue
soared upto 928.41 crore, a growth of 32 percent
For Panacea Biotec, the year 2010-11 has been
the year of collaborations and launch of new products. The company
registered a turnover of
928.41 crore in 2010-11 with an
impressive
growth of 32.05 percent over last year's revenue of
703.19 crore. This
is considered to be the firm's highest revenue since its foray into the
biotech arena.
The company recorded a net turnover of
1,130 crore with a growth rate
of 28 percent over last year. The revenue of the vaccine business of
the company stood at
833.22 crore, whereas the revenue from
the
therapeutics segment stood at
4.87 crore. The revenue from
biochemicals and other related products was
90.32 crore.
Panacea Biotec has spread its operations to more than 35 countries in
Latin America, South East Asia, CIS and Africa. The company set up
wholly owned subsidiaries in strategic markets like US, Germany,
Switzerland and UAE.
The company has collaborations with corporations like Novartis Vaccines
and Diagnostics, Sanofi Aventis, Netherland's Vaccine Institute,
PT BioFarma and National Institute of Health Biotechnology
Consortium of India.
The company is a partner to the UN Healthcare agencies in their polio
eradication initiative and supplies millions of doses of WHO
pre-qualified polio vaccines. Panacea Biotec has also introduced the
next gen inactivated polio vaccine (eIPV) in collaboration with the
Netherlands Vaccine Institute. eIPV is registered in Bangladesh and is
in an advanced stage of registration in more than 10 countries
worldwide.
The company supplied more than six billion doses of oral polio vaccine
to Government of India and UNICEF. The company also launched its
vaccines in Chile, Nepal and Pakistan and has supplied to Botswana and
Switzerland. The firm is expected to send its vaccines to Peru and
Philippines during Q1 of 2012.
During FY 2010-11, Panacea Biotec launched PacliALL at the Indian
Cancer Congress 2011. This product has been developed by Panacea's
state-of-the-art Global Research and Development (GRAND) Center, Navi
Mumbai. Furthermore, the company also launched EXEROZ-F and VERGRAF.
According to Dr Rajesh Jain, joint managing director, “We are extremely
happy with the significant financial progress made in 2010-11. Our
business strategy and its flawless execution has helped us deliver this
excellent growth.�
Recently, Panacea Biotec signed two non-exclusive marketing agreements
with Laboratorios Clausen, Uruguay, to market its Tacrolimus (Pangraf)
in defined markets in Europe.
Also, in a separate agreement of technology exchange, Panacea Biotec
agreed to explore the possibility of technology transfer of its product
to Laboratorios Clausen. In exchange, Laboratorios Clausen would
provide technology of mycophenolate mofetil (MMF) to Panacea Biotec.